Table 2.
Serum Antirotavirus Immunoglobulin A (IgA) Seroconversion After Vaccination
| Outcome | Group 1 (n = 142) |
Group 2 (n = 139) |
Group 3 (n = 143) |
Group 1 vs 3 |
Group 1 vs 2 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subjects, No. | Subjects, % (95% CI) | Subjects, No. | Subjects, % (95% CI) | Subjects, No. | Subjects, % (95% CI) | Percentage Point Difference (95% CI) | P Value | Percentage Point Difference (95% CI) | P Value | |
| Primary measurea | 41 | 28.9 (22.1–36.8) | 52 | 37.4 (29.8–45.7) | 62 | 43.4 (35.5–51.6) | 14.5 (3.3–25.1) | .014b | 8.5 (−2.5 to 19.3) | .163b |
| Group 1 measured at wk 14 only | 29 | 20.4 (14.6–27.8) | … | … | … | … | 22.9 (12.2–33.0) | <.001c | 17.0 (6.4–27.1) | .002c |
| Group 1 measured at wk 18 only | 35 | 24.7 (18.3–32.3) | … | … | … | … | 18.7 (7.7–29.1) | .001d | 12.8 (1.2–23.2) | .028d |
Group 1 received rotavirus vaccine at ages 6 and 10 weeks, group 2 received vaccine at ages 10 and 14 weeks, and group 3 received vaccine at ages 6, 10, and 14 weeks.
Abbreviation: CI, confidence interval.
a Of group 1 participants who seroconverted, 56.1% (23) demonstrated seroconversion at weeks 14 and 18, 14.6% (6) at week 14 only, and 29.3% (12) at week 18 only.
b Highest IgA seroconversion value at either 14 or 18 weeks for group 1 and at 18 weeks in groups 2 and 3.
c For the comparison of seroconversion frequency at wk 14 in group 1 to the frequency at wk 18 for group 2 or group 3.
d For the comparison of seroconversion frequency at wk 18 in groups 1, 2, and 3.